Chronic Administration of the Nitroxyl Donor 1-Nitrosocyclo Hexyl Acetate Limits Left Ventricular Diastolic Dysfunction in a Mouse Model of Diabetes Mellitus in Vivo

Circulation: Heart Failure

Volumn 8, Issue 3, 2015, Pages 572-581

  Cao, Nga ^a   Wong, Yung George ^a,b   Rosli, Sarah ^a   Kiriazis, Helen ^a   Huynh, Karina ^b   Qin, Chengxue ^a   Du, Xiao Jun ^a,b   Kemp Harper, Barbara K ^b   Ritchie, Rebecca H ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

cardiomyopathies; diabetes mellitus; diastolic heart failure; left ventricular hypertrophy; nitrates

Indexed keywords

1 NITROSOCYCLO HEXYL ACETATE; CARDIOVASCULAR AGENT; CYSTEINE; GLUCOSE; MITOCHONDRIAL PROTEIN; MITOCHONDRIAL UNCOUPLING PROTEIN 3; NITRIC OXIDE; STREPTOZOCIN; SUPEROXIDE; UNCLASSIFIED DRUG; 1-NITROSOCYCLOHEXYL ACETATE; ACETIC ACID DERIVATIVE; NITRIC OXIDE DONOR; NITROSO DERIVATIVE;

A WAVE; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SIZE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DECELERATION; DIABETIC CARDIOMYOPATHY; DIASTOLIC DYSFUNCTION; DRUG EFFICACY; E WAVE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EX VIVO STUDY; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; IN VIVO STUDY; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LUNG WEIGHT; M MODE ECHOCARDIOGRAPHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELAXATION TIME; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; UPREGULATION; ANIMAL; CORONARY BLOOD VESSEL; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; DIASTOLE; DOSE RESPONSE; DRUG EFFECTS; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HYPERTROPHY, LEFT VENTRICULAR; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PREVENTION AND CONTROL; VASODILATATION;

ACETATES; ANIMALS; CORONARY VESSELS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; DIASTOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERTROPHY, LEFT VENTRICULAR; MALE; MICE; MYOCYTES, CARDIAC; NITRIC OXIDE DONORS; NITROSO COMPOUNDS; SUPEROXIDES; VASODILATION; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84938545459     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.114.001699     Document Type: Article

References (48)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4-14. doi: 10.1016/j.diabres.2009.10.007.
2. Bell DS. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care. 2003;26:2433-2441.
3. Liu JE, Palmieri V, Roman MJ, Bella JN, Fabsitz R, Howard BV, Welty TK, Lee ET, Devereux RB. The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. J Am Coll Cardiol. 2001;37:1943-1949.
4. Huynh K, Bernardo BC, McMullen JR, Ritchie RH. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol Ther. 2014;142:375-415. doi: 10.1016/j. pharmthera.2014.01.003.
5. Irvine JC, Ritchie RH, Favaloro JL, Andrews KL, Widdop RE, Kemp-Harper BK. Nitroxyl (HNO): the Cinderella of the nitric oxide story. Trends Pharmacol Sci. 2008;29:601-608. doi: 10.1016/j. tips.2008.08.005.
6. Ritchie RH, Irvine JC, Rosenkranz AC, Patel R, Wendt IR, Horowitz JD, Kemp-Harper BK. Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO and beyond. Pharmacol Ther. 2009;124:279-300. doi: 10.1016/j.pharmthera.2009.08.001.
7. Bullen ML, Miller AA, Andrews KL, Irvine JC, Ritchie RH, Sobey CG, Kemp-Harper BK. Nitroxyl (HNO) as a vasoprotective signaling molecule. Antioxid Redox Signal. 2011;14:1675-1686. doi: 10.1089/ars.2010.3327.
8. Chin KY, Qin C, Cao N, Kemp-Harper BK, Woodman OL, Ritchie RH. The concomitant coronary vasodilator and positive inotropic actions of the nitroxyl donor Angeli's salt in the intact rat heart: contribution of soluble guanylyl cyclase-dependent and-independent mechanisms. Br J Pharmacol. 2014;171:1722-1734. doi: 10.1111/bph.12568.
9. Irvine JC, Favaloro JL, Widdop RE, Kemp-Harper BK. Nitroxyl anion donor, Angeli's salt, does not develop tolerance in rat isolated aortae. Hypertension. 2007;49:885-892. doi: 10.1161/01. HYP.0000259328.04159.90.
10. Irvine JC, Favaloro JL, Kemp-Harper BK. NO-activates soluble guanylate cyclase and Kv channels to vasodilate resistance arteries. Hypertension. 2003;41:1301-1307. doi: 10.1161/01.HYP.0000072010.54901.DE.
11. Paolocci N, Saavedra WF, Miranda KM, Martignani C, Isoda T, Hare JM, Espey MG, Fukuto JM, Feelisch M, Wink DA, Kass DA. Nitroxyl anion exerts redox-sensitive positive cardiac inotropy in vivo by calcitonin gene-related peptide signaling. Proc Natl Acad Sci USA. 2001;98:10463-10468. doi: 10.1073/pnas.181191198.
12. Irvine JC, Kemp-Harper BK, Widdop RE. Chronic administration of the HNO donor Angeli's salt does not lead to tolerance, cross-tolerance, or endothelial dysfunction: comparison with GTN and DEA/NO. Antioxid Redox Signal. 2011;14:1615-1624. doi: 10.1089/ars.2010.3269.
13. Paolocci N, Katori T, Champion HC, St John ME, Miranda KM, Fukuto JM, Wink DA, Kass DA. Positive inotropic and lusitropic effects of HNO/NO-in failing hearts: independence from beta-adrenergic signaling. Proc Natl Acad Sci USA. 2003;100:5537-5542. doi: 10.1073/pnas.0937302100.
14. Dai T, Tian Y, Tocchetti CG, Katori T, Murphy AM, Kass DA, Paolocci N, Gao WD. Nitroxyl increases force development in rat cardiac muscle. J Physiol. 2007;580(Pt.3):951-960. doi: 10.1113/jphysiol.2007.129254.
15. Lancel S, Zhang J, Evangelista A, Trucillo MP, Tong X, Siwik DA, Cohen RA, Colucci WS. Nitroxyl activates SERCA in cardiac myocytes via glutathiolation of cysteine 674. Circ Res. 2009;104:720-723. doi: 10.1161/CIRCRESAHA.108.188441.
16. Tocchetti CG, Stanley BA, Murray CI, Sivakumaran V, Donzelli S, Mancardi D, Pagliaro P, Gao WD, van Eyk J, Kass DA, Wink DA, Paolocci N. Playing with cardiac "redox switches": the "HNO way" to modulate cardiac function. Antioxid Redox Signal. 2011;14:1687-1698. doi: 10.1089/ars.2010.3859.
17. Tocchetti CG, Wang W, Froehlich JP, Huke S, Aon MA, Wilson GM, Di Benedetto G, O'Rourke B, Gao WD, Wink DA, Toscano JP, Zaccolo M, Bers DM, Valdivia HH, Cheng H, Kass DA, Paolocci N. Nitroxyl improves cellular heart function by directly enhancing cardiac sarcoplasmic reticulum Ca2+ cycling. Circ Res. 2007;100:96-104. doi: 10.1161/01. RES.0000253904.53601.c9.
18. Lin EQ, Irvine JC, Cao AH, Alexander AE, Love JE, Patel R, McMullen JR, Kaye DM, Kemp-Harper BK, Ritchie RH. Nitroxyl (HNO) stimulates soluble guanylyl cyclase to suppress cardiomyocyte hypertrophy and superoxide generation. PLoS One. 2012;7:e34892. doi: 10.1371/journal.pone.0034892.
19. Irvine JC, Cao N, Gossain S, Alexander AE, Love JE, Qin C, Horowitz JD, Kemp-Harper BK, Ritchie RH. HNO/cGMP-dependent antihypertrophic actions of isopropylamine-NONOate in neonatal rat cardiomyocytes: potential therapeutic advantages of HNO over NO. Am J Physiol Heart Circ Physiol. 2013;305:H365-H377. doi: 10.1152/ajpheart.00495.2012.
20. Sabbah HN, Tocchetti CG, Wang M, Daya S, Gupta RC, Tunin RS, Mazhari R, Takimoto E, Paolocci N, Cowart D, Colucci WS, Kass DA. Nitroxyl (HNO): a novel approach for the acute treatment of heart failure. Circ Heart Fail. 2013;6:1250-1258. doi: 10.1161/CIRCHEARTFAILURE.113.000632.
21. Tarone G, Balligand JL, Bauersachs J, Clerk A, De Windt L, Heymans S, Hilfiker-Kleiner D, Hirsch E, Iaccarino G, Knöll R, Leite-Moreira AF, Lourenço AP, Mayr M, Thum T, Tocchetti CG. Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. Eur J Heart Fail. 2014;16:494-508. doi: 10.1002/ejhf.62.
22. Huynh K, Kiriazis H, Du XJ, Love JE, Jandeleit-Dahm KA, Forbes JM, McMullen JR, Ritchie RH. Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes. Diabetologia. 2012;55:1544-1553. doi: 10.1007/s00125-012-2495-3.
23. Huynh K, Kiriazis H, Du XJ, Love JE, Gray SP, Jandeleit-Dahm KA, McMullen JR, Ritchie RH. Targeting the upregulation of reactive oxygen species subsequent to hyperglycemia prevents type 1 diabetic cardiomyopathy in mice. Free Radic Biol Med. 2013;60:307-317. doi: 10.1016/j. freeradbiomed.2013.02.021.
24. Shoman ME, DuMond JF, Isbell TS, Crawford JH, Brandon A, Honovar J, Vitturi DA, White CR, Patel RP, King SB. Acyloxy nitroso compounds as nitroxyl (HNO) donors: kinetics, reactions with thiols, and vasodilation properties. J Med Chem. 2011;54:1059-1070. doi: 10.1021/jm101432z.
25. Sha X, Isbell TS, Patel RP, Day CS, King SB. Hydrolysis of acyloxy nitroso compounds yields nitroxyl (HNO). J Am Chem Soc. 2006;128:9687-9692. doi: 10.1021/ja062365a.
26. El-Armouche A, Wahab A, Wittköpper K, Schulze T, Böttcher F, Pohlmann L, King SB, DuMond JF, Gerloff C, Böger RH, Eschenhagen T, Carrier L, Donzelli S. The new HNO donor, 1-nitrosocyclohexyl acetate, increases contractile force in normal and-adrenergically desensitized ventricular myocytes. Biochem Biophys Res Commun. 2010;402:340-344. doi: 10.1016/j.bbrc.2010.10.030.
27. Huynh K, McMullen JR, Julius TL, Tan JW, Love JE, Cemerlang N, Kiriazis H, Du XJ, Ritchie RH. Cardiac-specific IGF-1 receptor transgenic expression protects against cardiac fibrosis and diastolic dysfunction in a mouse model of diabetic cardiomyopathy. Diabetes. 2010;59:1512-1520. doi: 10.2337/db09-1456.
28. Ritchie RH, Love JE, Huynh K, Bernardo BC, Henstridge DC, Kiriazis H, Tham YK, Sapra G, Qin C, Cemerlang N, Boey EJ, Jandeleit-Dahm K, Du XJ, McMullen JR. Enhanced phosphoinositide 3-kinase(p110) activity prevents diabetes-induced cardiomyopathy and superoxide generation in a mouse model of diabetes. Diabetologia. 2012;55:3369-3381. doi: 10.1007/s00125-012-2720-0.
29. Xu Q, Dalic A, Fang L, Kiriazis H, Ritchie RH, Sim K, Gao XM, Drummond G, Sarwar M, Zhang YY, Dart AM, Du XJ. Myocardial oxidative stress contributes to transgenic 2-adrenoceptor activation-induced cardiomyopathy and heart failure. Br J Pharmacol. 2011;162:1012-1028. doi: 10.1111/j.1476-5381.2010.01043.x.
30. Choi KM, Zhong Y, Hoit BD, Grupp IL, Hahn H, Dilly KW, Guatimosim S, Lederer WJ, Matlib MA. Defective intracellular Ca(2+) signaling contributes to cardiomyopathy in Type 1 diabetic rats. Am J Physiol Heart Circ Physiol. 2002;283:H1398-H1408. doi: 10.1152/ajpheart.00313.2002.
31. Ligeti L, Szenczi O, Prestia CM, Szabó C, Horváth K, Marcsek ZL, van Stiphout RG, van Riel NA, Op den Buijs J, Van der Vusse GJ, Ivanics T. Altered calcium handling is an early sign of streptozotocin-induced diabetic cardiomyopathy. Int J Mol Med. 2006;17:1035-1043.
32. Bidasee KR, Zhang Y, Shao CH, Wang M, Patel KP, Dincer UD, Besch HR Jr. Diabetes increases formation of advanced glycation end products on Sarco(endo)plasmic reticulum Ca2+-ATPase. Diabetes. 2004;53:463-473.
33. Heerdt PM, Lane P, Pan BY, Schaefer U, Crabtree M, Hong R, Singer AA, Levi R, Park BJ. Nitrosative stress and myocardial sarcoplasmic endoreticular calcium adenosine triphosphatase subtype 2a activity after lung resection in swine. Anesthesiology. 2007;107:954-962. doi: 10.1097/01.anes.0000291446.70921.61.
34. Ying J, Sharov V, Xu S, Jiang B, Gerrity R, Schöneich C, Cohen RA. Cysteine-674 oxidation and degradation of sarcoplasmic reticulum Ca(2+) ATPase in diabetic pig aorta. Free Radic Biol Med. 2008;45:756-762. doi: 10.1016/j.freeradbiomed.2008.05.029.
35. Kohr MJ, Kaludercic N, Tocchetti CG, Dong Gao W, Kass DA, Janssen PM, Paolocci N, Ziolo MT. Nitroxyl enhances myocyte Ca2+ transients by exclusively targeting SR Ca2+-cycling. Front Biosci (Elite Ed). 2010;2:614-626.
36. Matsushima S, Kinugawa S, Ide T, Matsusaka H, Inoue N, Ohta Y, Yokota T, Sunagawa K, Tsutsui H. Overexpression of glutathione peroxidase attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Am J Physiol Heart Circ Physiol. 2006;291:H2237-H2245. doi: 10.1152/ajpheart.00427.2006.
37. Tsutsui H, Matsushima S, Kinugawa S, Ide T, Inoue N, Ohta Y, Yokota T, Hamaguchi S, Sunagawa K. Angiotensin II type 1 receptor blocker attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Hypertens Res. 2007;30:439-449. doi: 10.1291/hypres.30.439.
38. Aneja A, Tang WH, Bansilal S, Garcia MJ, Farkouh ME. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med. 2008;121:748-757. doi: 10.1016/j. amjmed.2008.03.046.
39. Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, Tikellis C, Ritchie RH, Twigg SM, Cooper ME, Burrell LM. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res. 2003;92:785-792. doi: 10.1161/01. RES.0000065620.39919.20.
40. Chang KC, Tseng CD, Chou TF, Cho YL, Chi TC, Su MJ, Tseng YZ. Arterial stiffening and cardiac hypertrophy in a new rat model of type 2 diabetes. Eur J Clin Invest. 2006;36:1-7. doi: 10.1111/j.1365-2362.2006.01588.x.
41. Connelly KA, Kelly DJ, Zhang Y, Prior DL, Martin J, Cox AJ, Thai K, Feneley MP, Tsoporis J, White KE, Krum H, Gilbert RE. Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat. Cardiovasc Res. 2007;76:280-291. doi: 10.1016/j. cardiores.2007.06.022.
42. Fiordaliso F, Li B, Latini R, Sonnenblick EH, Anversa P, Leri A, Kajstura J. Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II-dependent. Lab Invest. 2000;80:513-527.
43. Fiordaliso F, De Angelis N, Bai A, Cuccovillo I, Salio M, Serra DM, Bianchi R, Razzetti R, Latini R, Masson S. Effect of beta-adrenergic and renin-angiotensin system blockade on myocyte apoptosis and oxidative stress in diabetic hypertensive rats. Life Sci. 2007;81:951-959. doi: 10.1016/j.lfs.2007.05.027.
44. Li CG, Karagiannis J, Rand MJ. Comparison of the redox forms of nitrogen monoxide with the nitrergic transmitter in the rat anococcygeus muscle. Br J Pharmacol. 1999;127:826-834. doi: 10.1038/sj.bjp.0702540.
45. Flores-Santana W, Salmon DJ, Donzelli S, Switzer CH, Basudhar D, Ridnour L, Cheng R, Glynn SA, Paolocci N, Fukuto JM, Miranda KM, Wink DA. The specificity of nitroxyl chemistry is unique among nitrogen oxides in biological systems. Antioxid Redox Signal. 2011;14:1659-1674. doi: 10.1089/ars.2010.3841.
46. Solaro RJ. Nitroxyl effects on myocardium provide new insights into the significance of altered myofilament response to calcium in the regulation of contractility. J Physiol. 2007;580(Pt.3):697. doi: 10.1113/jphysiol.2007.131649.
47. Sivakumaran V, Stanley BA, Tocchetti CG, Ballin JD, Caceres V, Zhou L, Keceli G, Rainer PP, Lee DI, Huke S, Ziolo MT, Kranias EG, Toscano JP, Wilson GM, O'Rourke B, Kass DA, Mahaney JE, Paolocci N. HNO enhances SERCA2a activity and cardiomyocyte function by promoting redox-dependent phospholamban oligomerization. Antioxid Redox Signal. 2013;19:1185-1197. doi: 10.1089/ars.2012.5057.
48. Pfeiffer S, Leopold E, Hemmens B, Schmidt K, Werner ER, Mayer B. Interference of carboxy-PTIO with nitric oxide-and peroxynitrite-mediated reactions. Free Radic Biol Med. 1997;22:787-794.